drugset / Trial / NCT01594827

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The prevalence of methicillin resistant Staphylococcus aureus (MRSA) respiratory infection in Cystic Fibrosis (CF) has increased dramatically over the last decade. Evidence suggests that persistent infection with MRSA may result in an increased rate of decline in Forced Expiratory Volume (FEV)1 and shortened survival. Currently there are no conclusive studies demonstrating an effective aggressive treatment protocol for persistent MRSA respiratory infection in CF. Data demonstrating an effective and safe method of clearing persistent MRSA infection are needed. The purpose of this study is to evaluate the safety and efficacy of a 28-day course of vancomycin for inhalation, 250 mg twice a day, (in combination with oral antibiotics) in eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA infection. Subjects will be assigned in a 1:1 ratio to either vancomycin for inhalation (250 mg twice a day) or taste matched placebo and will be followed for 3 additional months. In addition, both groups will receive oral rifampin, a second oral antibiotic (TMP-SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Forty patients with persistent respiratory tract MRSA infection will be enrolled in this trial.

Timeline

Start
2012-10
Primary completion
2017-12-30
Completion
2017-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 250 mg Inhaled
Background Chlorhexidine gluconate Other / unclassified 4 % Topical
Background Doxycycline Small molecule 50 mg Oral
Background Doxycycline Small molecule 75 mg Oral
Background Doxycycline Small molecule 100 mg Oral
Background Mupirocin Small molecule 2 % Intranasal
Background Rifampin Small molecule 300 mg Oral
Background Rifampin Small molecule 450 mg Oral
Background Rifampin Small molecule 600 mg Oral
Background Trimethoprim/Sulfamethoxazole Unknown 160 mg Oral
Background Trimethoprim/Sulfamethoxazole Unknown 320 mg Oral

Indications